Impaired fasting glucose as a treatment target in diabetes management

Robert Chilton, Rene A. Oliveros, Adrienne S. Zion, Yelena Rosenberg, Carrie Lynn Selvaraj

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Impaired fasting glucose (IFG) contributes to microvascular and macrovascular complications and increased cardiovascular disease risk. Although type 2 diabetes is largely considered to occur as a result of IFG, understanding of physiologic and associated management targets is uniformly lacking among health care professionals. Once definitions are standardized, diagnostic criteria and screening tools may help to identify individuals at risk sooner, thereby minimizing the rapid deterioration that often results. To counter the rising pandemic of obesity and diabetes, it is important to understand the vascular risk of IFG and impaired glucose tolerance in patients at risk.

Original languageEnglish (US)
Pages (from-to)460-467
Number of pages8
JournalCurrent Cardiology Reports
Issue number6
StatePublished - Nov 2009

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Impaired fasting glucose as a treatment target in diabetes management'. Together they form a unique fingerprint.

Cite this